Article
Molecular genetic aspects of myelodysplastic syndromes.
Hematology/oncology clinics of North America - 1 Jun 1992
Bartram C R
Abstract excerpt
Myelodysplastic syndromes originate from a pluripotent stem cell. This view, previously suggested by G-6-PD and cytogenetic investigations, has been established unequivocally by X-chromosome inactivation analysis based on DNA polymorphisms and by studies of mutated oncogenes. Two genomic alterations associated with MDS have been analyzed in more detail. Activation of the RAS oncogenes, preferentially N-RAS, is...
Topics
- Chromosome Deletion
- Dosage Compensation, Genetic
- Genes, Tumor Suppressor
- Genes, fms
- Genes, ras
- Humans
- Mutation
- Myelodysplastic Syndromes